New FDA Approval for CML Patients

Asciminib (Scemblix) was recently approved for the following indications:

For patients with Philadelphia chromosome– positive chronic myeloid leukemia (Ph+ CML) in chronic phase who have been previously treated with two or more tyrosine kinase inhibitors.

For patients with Ph+ CML in chronic phase with a T315I mutation

Here at Belong, we will continue to update you with new medical and research developments. If you are interested in clinical trial-related info or in participating in such a trial, you are invited to respond here or contact us in the “Find Clinical Trials” group.

Best of health,
The Clinical Trial Team

For more info:

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia

This content is provided for your general education and information only. It does not necessarily reflect Belong’s views and opinions. Belong does not endorse or support any specific product, service or treatment

More Articles

How Does Cold Weather Affect MS?

For people with multiple sclerosis (MS), the arrival of cold weather may bring challenges. Here…

What is Chemo Brain

If you’re currently undergoing chemotherapy, you might have come across the term ”chemo brain”. Chemo…

The Flu and Multiple Sclerosis

Many of you may have wondered if the flu triggers multiple sclerosis symptoms….

Cancer-Related Fatigue

Have you ever wondered why cancer-related fatigue feels different from just feeling tired? Let’s explore…

What is Pityriasis Rosea?

Pityriasis rosea is a common skin condition characterized by the appearance of a large, scaly…

Exercise after Treatment

Exercise is key to your recovery journey, helping you regain physical strength, boost your mood,…
Skip to content